SELLAS Reports Updated Results from its P-IIa Study of SLS009 (formerly GFH009) for R/R Acute Myeloid Leukemia (AML)
Shots:
- The P-IIa study investigates SLS009’s safety, tolerability, and efficacy combined with venetoclax/azacitidine at two dose levels (45mg and 60mg) having 5-10 participants in each arm
- The updated follow-up data from 2-7mos. revealed that 8/9 (89%) patients are alive across 45mg safety dose level and 6 continue the treatment. 1st patient has attained CR. ≥50% reduction in bone marrow blasts was seen in 7/8 (87.5%) evaluable patients. DLTs were not reported. Additional results from the 45mg arm and initial data from the 60mg (RP2D level) arm are anticipated in Q1’24 while 60mg cohort analysis is expected in Q2’24
- Additionally, the company’s SLS009 has received FTD by the US FDA to treat r/r AML
Ref: Sellas | Image: Sellas
Related News:- SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
